Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.CARM · Entity 74418 | Director | June 06, 2023 | June 08, 2023 |
| Rainier Acquisition CorpRNAQ · Entity 527 | Director | August 26, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2033-06-06 | Direct | 38,700 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 38,700 · Balance 38,700 F1: The shares underlying this option vest over three years in equal monthly installments following June 6, 2023, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest over three years in equal monthly installments following June 6, 2023, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.
Rainier Acquisition Corp
Report date August 26, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each Class B ordinary share is convertible into one Class A ordinary share at the option of the holder, and will automatically convert at the time of the Issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis. The Class B ordinary shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Class B ordinary share is convertible into one Class A ordinary share at the option of the holder, and will automatically convert at the time of the Issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis. The Class B ordinary shares have no expiration date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Clene Inc.
Report date July 17, 2026 · Filed August 06, 2026
Section 16 reporting ended · disclosed 2026-08-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common Stock (Tranche B, $30.00 strike)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2030-06-16 | IndirectBy SymBiosis II LLC | 0 |
Reported balance
After 2026-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-17 · Other · Disposed 375,000 · Balance 0 F1: The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred. F3: The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received. F2: Currently exercisable |
| Common Stock Purchase Warrant ($4.82 strike)SEC Table II · derivative / convertible security · Conversion / exercise price $4.82 · Expires 2029-09-30 | IndirectBy SymBiosis II LLC | 0 |
Reported balance
After 2026-07-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-17 · Other · Disposed 424,358 · Balance 0 F1: The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred. F3: The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received. F2: Currently exercisable |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred.
F2: Currently exercisable
F3: The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received.
Tessera Defense & Homeland Security Inc.
Report date October 17, 2022 · Filed November 14, 2022
Section 16 reporting ended · disclosed 2022-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy SymBiosis, LLC | 2,997,025 |
Last balance in matching sequence
After 2022-11-04 transaction · row 15
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
15 source rowsRow 1 · 2022-10-17 · Sale · Disposed 8,098 · Balance 3,063,882 F1: The shares are directly held by SymBiosis, LLC. Row 2 · 2022-10-18 · Sale · Disposed 15,300 · Balance 3,048,582 F1: The shares are directly held by SymBiosis, LLC. Row 3 · 2022-10-19 · Sale · Disposed 4,501 · Balance 3,044,081 F1: The shares are directly held by SymBiosis, LLC. Row 4 · 2022-10-20 · Sale · Disposed 6,636 · Balance 3,037,445 F1: The shares are directly held by SymBiosis, LLC. Row 5 · 2022-10-21 · Sale · Disposed 5,400 · Balance 3,032,045 F1: The shares are directly held by SymBiosis, LLC. Row 6 · 2022-10-24 · Sale · Disposed 5,900 · Balance 3,026,145 F1: The shares are directly held by SymBiosis, LLC. Row 7 · 2022-10-25 · Sale · Disposed 3,072 · Balance 3,023,073 F1: The shares are directly held by SymBiosis, LLC. Row 8 · 2022-10-26 · Sale · Disposed 12,500 · Balance 3,010,573 F1: The shares are directly held by SymBiosis, LLC. Row 9 · 2022-10-27 · Sale · Disposed 1,505 · Balance 3,009,068 F1: The shares are directly held by SymBiosis, LLC. Row 10 · 2022-10-28 · Sale · Disposed 1,526 · Balance 3,007,542 F1: The shares are directly held by SymBiosis, LLC. Row 11 · 2022-10-31 · Sale · Disposed 3,300 · Balance 3,004,242 F1: The shares are directly held by SymBiosis, LLC. Row 12 · 2022-11-01 · Sale · Disposed 1,300 · Balance 3,002,942 F1: The shares are directly held by SymBiosis, LLC. Row 13 · 2022-11-02 · Sale · Disposed 2,416 · Balance 3,000,526 F1: The shares are directly held by SymBiosis, LLC. Row 14 · 2022-11-03 · Sale · Disposed 2,000 · Balance 2,998,526 F1: The shares are directly held by SymBiosis, LLC. Row 15 · 2022-11-04 · Sale · Disposed 1,501 · Balance 2,997,025 F1: The shares are directly held by SymBiosis, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are directly held by SymBiosis, LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2026 Filed Aug 6, 2026 17:32 UTC | Clene Inc. CLNN · Entity 7166 | OtherCommon Stock Purchase Warrant ($4.82 strike) · Derivative | 424,358 | Not disclosed Strike: $4.82 | Not disclosed |
DisclosureSEC source: 0001835544-26-000022 · primary_doc.xml · derivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II LLC Disclosed balance after: 0 Underlying: Common Stock · 424,358 shares Expires 2029-09-30 F1 · kind: The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred. F3 · price: The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received. F2 · derivative.exercise_date: Currently exercisable Read SEC document |
| July 17, 2026 Filed Aug 6, 2026 17:32 UTC | Clene Inc. CLNN · Entity 7166 | OtherWarrant to Purchase Common Stock (Tranche B, $30.00 strike) · Derivative | 375,000 | Not disclosed Strike: $30.00 | Not disclosed |
DisclosureSEC source: 0001835544-26-000022 · primary_doc.xml · derivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II LLC Disclosed balance after: 0 Underlying: Common Stock · 375,000 shares Expires 2030-06-16 F1 · kind: The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred. F3 · price: The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received. F2 · derivative.exercise_date: Currently exercisable Read SEC document |
| May 12, 2026 Filed May 13, 2026 22:04 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 73,296 | $6.20 | $454,435.20 |
DisclosureSEC source: 0001835544-26-000019 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 103,417 Read SEC document |
| May 11, 2026 Filed May 13, 2026 22:04 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 22,177 | $6.75 | $149,694.75 |
DisclosureSEC source: 0001835544-26-000019 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 176,713 Read SEC document |
| May 04, 2026 Filed May 5, 2026 21:53 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 72,884 | $6.80 | $495,611.20 |
DisclosureSEC source: 0001835544-26-000018 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 198,890 Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:53 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 5,795 | $6.01 | $34,827.95 |
DisclosureSEC source: 0001835544-26-000018 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 271,774 Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 21:54 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 5,736 | $6.08 | $34,874.88 |
DisclosureSEC source: 0001835544-26-000017 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 277,569 Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 21:54 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 12,170 | $5.63 | $68,517.10 |
DisclosureSEC source: 0001835544-26-000017 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 283,305 Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 21:54 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 1,591 | $5.90 | $9,386.90 |
DisclosureSEC source: 0001835544-26-000017 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 295,475 Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 21:55 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 61,345 | $6.14 | $376,658.30 |
DisclosureSEC source: 0001835544-26-000016 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 297,066 Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:55 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 4,318 | $6.12 | $26,426.16 |
DisclosureSEC source: 0001835544-26-000016 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 358,411 Read SEC document |
| April 17, 2026 Filed Apr 18, 2026 00:17 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 25,040 | $6.43 | $161,007.20 |
DisclosureSEC source: 0001835544-26-000015 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 362,729 Read SEC document |
| April 16, 2026 Filed Apr 18, 2026 00:17 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 7,748 | $6.40 | $49,587.20 |
DisclosureSEC source: 0001835544-26-000015 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 387,769 Read SEC document |
| April 15, 2026 Filed Apr 18, 2026 00:17 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 6,374 | $6.48 | $41,303.52 |
DisclosureSEC source: 0001835544-26-000015 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 395,517 Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 21:32 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 24,925 | $4.81 | $119,889.25 |
DisclosureSEC source: 0001835544-26-000014 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 401,891 Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 21:10 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 4,278 | $4.97 | $21,261.66 |
DisclosureSEC source: 0001835544-26-000013 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 426,816 Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 20:35 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 67,991 | $4.88 | $331,796.08 |
DisclosureSEC source: 0001835544-26-000012 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 431,094 Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:35 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 15,536 | $5.10 | $79,233.60 |
DisclosureSEC source: 0001835544-26-000012 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 499,085 Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:35 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 17,470 | $4.75 | $82,982.50 |
DisclosureSEC source: 0001835544-26-000012 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 514,621 Read SEC document |
| March 26, 2026 Filed Mar 26, 2026 21:39 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 5,319 | $5.40 | $28,722.60 |
DisclosureSEC source: 0001835544-26-000011 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 532,091 Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 21:39 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 7,098 | $5.50 | $39,039.00 |
DisclosureSEC source: 0001835544-26-000011 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 537,410 Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 21:39 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 5,492 | $5.78 | $31,743.76 |
DisclosureSEC source: 0001835544-26-000011 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 544,508 Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 15:18 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 5,559 | $4.10 | $22,791.90 |
DisclosureSEC source: 0001835544-26-000010 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 550,000 Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 22:10 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 3,800 | $4.04 | $15,352.00 |
DisclosureSEC source: 0001835544-26-000009 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 555,559 Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:10 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 5,686 | $4.13 | $23,483.18 |
DisclosureSEC source: 0001835544-26-000009 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 559,359 Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 22:10 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 15,284 | $4.32 | $66,026.88 |
DisclosureSEC source: 0001835544-26-000009 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 565,045 Read SEC document |
| January 28, 2026 Filed Jan 28, 2026 22:01 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 8,717 | $4.91 | $42,800.47 |
DisclosureSEC source: 0001835544-26-000008 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By SymBiosis II, LLC Disclosed balance after: 580,329 Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 22:01 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 4,139 | $5.08 | $21,026.12 |
DisclosureSEC source: 0001835544-26-000008 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 589,046 Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 22:01 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 6,418 | $5.02 | $32,218.36 |
DisclosureSEC source: 0001835544-26-000008 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 593,185 Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:33 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 5,556 | $5.27 | $29,280.12 |
DisclosureSEC source: 0001835544-26-000007 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 599,603 Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 22:33 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 12,665 | $5.32 | $67,377.80 |
DisclosureSEC source: 0001835544-26-000007 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 605,159 Read SEC document |
| January 21, 2026 Filed Jan 21, 2026 23:13 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 12,119 | $5.05 | $61,200.95 |
DisclosureSEC source: 0001835544-26-000006 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 617,824 Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 23:13 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 12,432 | $4.80 | $59,673.60 |
DisclosureSEC source: 0001835544-26-000006 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 629,943 Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 23:13 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 7,923 | $5.13 | $40,644.99 |
DisclosureSEC source: 0001835544-26-000006 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 642,375 Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 16:16 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 12,563 | $5.10 | $64,071.30 |
DisclosureSEC source: 0001835544-26-000005 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 650,298 Read SEC document |
| January 14, 2026 Filed Jan 16, 2026 16:16 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 19,621 | $5.12 | $100,459.52 |
DisclosureSEC source: 0001835544-26-000005 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 662,861 Read SEC document |
| January 13, 2026 Filed Jan 16, 2026 16:16 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 26,105 | $4.89 | $127,653.45 |
DisclosureSEC source: 0001835544-26-000005 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 682,482 Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 21:38 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 32,705 | $5.50 | $179,877.50 |
DisclosureSEC source: 0001835544-26-000003 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 708,587 Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 21:38 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 9,075 | $6.27 | $56,900.25 |
DisclosureSEC source: 0001835544-26-000003 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 741,292 Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:38 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 3,195 | $6.09 | $19,457.55 |
DisclosureSEC source: 0001835544-26-000003 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 750,367 Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 22:28 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 3,938 | $6.29 | $24,770.02 |
DisclosureSEC source: 0001835544-26-000002 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 753,562 Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 22:28 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 3,111 | $6.04 | $18,790.44 |
DisclosureSEC source: 0001835544-26-000002 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 757,500 Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 22:28 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 5,869 | $5.87 | $34,451.03 |
DisclosureSEC source: 0001835544-26-000002 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 760,611 Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 22:25 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 4,015 | $5.73 | $23,005.95 |
DisclosureSEC source: 0001835544-26-000001 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 766,480 Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:25 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 13,095 | $5.81 | $76,081.95 |
DisclosureSEC source: 0001835544-26-000001 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 770,495 Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 17:10 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 4,138 | $6.03 | $24,952.14 |
DisclosureSEC source: 0001835544-25-000006 · primary_doc.xml · nonDerivative · entry 2 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 783,590 Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 17:10 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 8,096 | $5.95 | $48,171.20 |
DisclosureSEC source: 0001835544-25-000006 · primary_doc.xml · nonDerivative · entry 1 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 787,728 Read SEC document |
| December 26, 2025 Filed Dec 31, 2025 02:03 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 3,350 | $6.32 | $21,172.00 |
DisclosureSEC source: 0001835544-25-000005 · primary_doc.xml · nonDerivative · entry 4 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 795,824 Read SEC document |
| December 24, 2025 Filed Dec 31, 2025 02:03 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 1,490 | $6.27 | $9,342.30 |
DisclosureSEC source: 0001835544-25-000005 · primary_doc.xml · nonDerivative · entry 3 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 799,174 Read SEC document |
| December 23, 2025 Filed Dec 31, 2025 02:03 UTC | Clene Inc. CLNN · Entity 7166 | OtherPre-Funded Warrant to Purchase Common Stock · Derivative | 424,358 | $4.59 Strike: $0.00 | $1,946,530.15 |
DisclosureSEC source: 0001835544-25-000005 · primary_doc.xml · derivative · entry 5 Ugwumba Chidozie · CIK 0001835544 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Symbiosis II, LLC Disclosed balance after: 0 Underlying: Common Stock · 424,358 shares Expires not disclosed F2 · derivative.expiration_date: The pre-funded warrants are indefinite with no specified termination date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.